PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1200
- Registration Number
- NCT05387980
- Locations
- 🇯🇵
Pfizer Local Country Office, Tokyo, Japan
A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT05386472
- Locations
- 🇺🇸
University of Alabama at Birmingham/Center for Women's Reproductive Health, Birmingham, Alabama, United States
🇺🇸Beautiful Minds Clinical Research Center, Cutler Bay, Florida, United States
🇺🇸Omega Research Debary, DeBary, Florida, United States
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
- Conditions
- Metastatic HER2+ Advanced Breast CancerBreast NeoplasmsGastric or Gastroesophageal Junction Adenocarcinoma (GEC)Colorectal Cancer
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT05382364
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital-oncology of department ( Site 0010), Harbin, Heilongjiang, China
🇨🇳Hunan Cancer Hospital-Digestion and Urology ( Site 0008), Changsha, Hunan, China
🇨🇳Jilin Cancer Hospital-oncology department ( Site 0007), Changchun, Jilin, China
This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 255
- Registration Number
- NCT05375942
- Locations
- 🇺🇸
Pfizer, Collegeville, Pennsylvania, United States
A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 189
- Registration Number
- NCT05375929
- Locations
- 🇮🇳
Nirmal Hospital Pvt Ltd., Surat, Gujarat, India
🇮🇳All India Institute of Medical Sciences, New Delhi, Delhi, India
🇮🇳S. P. Medical College & A. G. Hospitals, Bikaner, Rajasthan, India
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
- Conditions
- Plaque PsoriasisAtopic Dermatitis
- Interventions
- Drug: PF-07038124 ointment 0.01%Drug: PF-07038124 ointment 0.06%Drug: PF-07038124 ointment 0.03%Drug: Vehicle ointment
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 263
- Registration Number
- NCT05375955
- Locations
- 🇺🇸
Texas Dermatology and Laser Specialists, San Antonio, Texas, United States
🇨🇦Lynderm Research Inc., Markham, Ontario, Canada
🇺🇸Renaissance Research and Medical Group, Cape Coral, Florida, United States
A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants
- Conditions
- Acute Migraine
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 241
- Registration Number
- NCT05371652
- Locations
- 🇨🇳
Wuhan Third Hospital, Wuhan, Hubei, China
🇨🇳The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHINESE CHILDREN AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS
- Conditions
- Immunogenicity, Vaccine
- Interventions
- Biological: PCV13 PAC study
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT05372575
- Locations
- 🇨🇳
Children's Hospital of Soochow University, Suzhou, Jiangsu, China
Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 17
- Registration Number
- NCT05363488
- Locations
- 🇬🇧
eatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: Aromatase inhibitor
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2888
- Registration Number
- NCT05361655
- Locations
- 🇺🇸
10017, New York, New York, United States